<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03352986</url>
  </required_header>
  <id_info>
    <org_study_id>003</org_study_id>
    <nct_id>NCT03352986</nct_id>
  </id_info>
  <brief_title>Substudy of CADRE: for People With Extreme Phenotype: BIOCADRE</brief_title>
  <acronym>BIOCADRE</acronym>
  <official_title>A Substudy of the CADRE Study: Determination of Clinical Markers in Patients With Extreme Sickle Cell Disease Phenotype</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiologie et Développement</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cardiologie et Développement</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      BIOCADRE is a CADRE substudy and aims to characterize more precisely the sickle cell patients
      with extreme phenotype.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sickle cell disease (SCD) is the most frequent monogenic disease in the world, due to a
      unique mutation on the β-globin gene. Most affected individuals live in sub-Saharan Africa,
      yet, the natural history of the disease in Africa remains largely unknown. SCD usually
      presents in childhood and is characterized by the association of a chronic hemolytic anemia
      with episodes of acute vaso-occlusive events and progressive vascular organ damage. SCD is
      now widely recognized as a vascular disease with marked endothelial dysfunction. Hemolysis
      probably plays a key role by reducing NO bioavailability, but other involved mechanisms are
      not fully understood.

      The project aims at better understanding SCD chronic vascular complications and in particular
      to explore extensively the different mechanisms associated with hemolysis. This will be
      addressed through both an epidemiological approach and a hypotheses-driven pathophysiological
      approach. On the one hand, a descriptive and analytic epidemiological study will isolate
      clusters of clinical, functional and usual biological phenotypes in SCD patients and look for
      new mechanistic and biological markers predictive of chronic vascular complications in SCD
      with SS phenotype. Investigators will specifically investigate i) microcirculation functions
      using peripheral arterial tonometry, ii) blood and plasma viscosities, iii) level of plasma
      blood cell derived microparticles, free hemoglobin, and the free heme content of
      erythrocytes-derived microparticles and expression of Duffy erythrocyte antigen, the unique
      erythroid receptor for chemokines. One the other hand, investigators will test novel markers
      and modifiers of hemolysis and heme metabolism and assess their relationship with
      inflammation and vascular phenotypes.These different biomarkers will be compared between the
      selected subgroups of patients with extreme vascular phenotype.

      Methods: The project involves a transversal case control study, nested in the CADRE cohort,
      recently built up by Partner 1 and African collaborators. CADRE is the largest ongoing
      epidemiological cohort, including 4,300 SCD patients and 1,000 controls in five west and
      central African countries, in which various chronic complications of SCD have already been
      registered. The present second phase study will be conducted in the centres of Dakar and
      Bamako. Patients' selection will be performed in the existing database to obtain 6 subgroups
      of 40 SS patients with one of the main vascular chronic complications or none of them, for a
      total of 240 patients. Selected patients will be recalled during one year in parallel in the
      2 recruiting centres. Clinical phenotyping, usual biology, functional microvascular functions
      (peripheral arterial tonometry), and blood/plasma viscosities analyses will be performed in
      the African recruiting centres after training of technicians, PhD and MD students by the
      French partners. Plasma samples, microparticles and extracellular DNA, will be prepared and
      frozen for further analyses in the partner's laboratories. DNA will be collected for each
      subject. A principal component analysis will isolate clusters of clinical complications,
      functional and biological markers and a multivariate logistic regression will quantify the
      effect of these markers on the risk of vasculopathy, with adjustment on all known SCD
      modifying factors.

      Expected results: 1) The identification of high risk SCD patients for chronic vascular
      complications using new biomarkers, 2) A better understanding of chronic vascular disease
      process at the mechanistic and biological (viscosity, hemolysis, erythrocyte derived
      microparticles, inflammatory cytokines and receptors) levels, 3) The identification of
      endophenotypes and constitution of DNA bank for further genetic studies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Description of microcirculation by peripheral arterial tonometry</measure>
    <time_frame>1 year</time_frame>
    <description>EndoPAT2000®, Itamar Medical Ltd,</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure of blood viscosities</measure>
    <time_frame>1 year</time_frame>
    <description>In whole blood by viscosimeter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage of microparticles</measure>
    <time_frame>1 year</time_frame>
    <description>In plasma: microparticles of erythrocytic, platelet, monocytic, neutrophilic and endothelial origin by flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of free hemoglobin</measure>
    <time_frame>1 year</time_frame>
    <description>In plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of neutrophil extracellular trap (NET)</measure>
    <time_frame>1 year</time_frame>
    <description>In plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of proinflammatory cytokines by ELISA</measure>
    <time_frame>1 year</time_frame>
    <description>In plasma by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genotyping of the alpha-globin gene associated with persistence of fetal hemoglobin</measure>
    <time_frame>1 year</time_frame>
    <description>In saliva DNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genotyping of the polymorphisms associated with persistence of fetal hemoglobin</measure>
    <time_frame>1 year</time_frame>
    <description>In saliva DNA</description>
  </secondary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>osteonecrosis</arm_group_label>
    <description>Sickle cell patients with osteonecrosis as a vascular main complication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>leg ulcer</arm_group_label>
    <description>Sickle cell patients with leg ulcer as a vascular main complication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>microalbuminuria</arm_group_label>
    <description>Sickle cell patients with microalbuminuria as a vascular main complication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pulmonary hypertension</arm_group_label>
    <description>Sickle cell patients with pulmonary hypertension as a vascular main complication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>stroke</arm_group_label>
    <description>Sickle cell patients with strocke as a vascular main complication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>priapism</arm_group_label>
    <description>Sickle cell patients with priapism as a vascular main complication</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>biological analysis</intervention_name>
    <description>biological analysis will be performed in the 6 groups of patients</description>
    <arm_group_label>osteonecrosis</arm_group_label>
    <arm_group_label>leg ulcer</arm_group_label>
    <arm_group_label>microalbuminuria</arm_group_label>
    <arm_group_label>pulmonary hypertension</arm_group_label>
    <arm_group_label>stroke</arm_group_label>
    <arm_group_label>priapism</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>peripheral arterial tonometry</intervention_name>
    <description>peripheral arterial tonometry will be performed in the 6 groups of patients</description>
    <arm_group_label>osteonecrosis</arm_group_label>
    <arm_group_label>leg ulcer</arm_group_label>
    <arm_group_label>microalbuminuria</arm_group_label>
    <arm_group_label>pulmonary hypertension</arm_group_label>
    <arm_group_label>stroke</arm_group_label>
    <arm_group_label>priapism</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      3 ml of saliva for DNA extraction (sample with DNA) and 2 ml of plasma (sample with no DNA)
      are taken.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population is sickle cell patients with extreme phenotypes (SS-hemoglobin) with a
        steady state.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  sickle cell patients with extreme phenotypes: SS-hemoglobin

        Exclusion Criteria:

          -  transfusion in the previous 2 months

          -  vaso-occlusive crisis in the previous 15 days

          -  infection in the previous 8 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Brigitte Ranque, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut National de la Santé Et de la Recherche Médicale, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brigitte Ranque, MD</last_name>
    <phone>0156092772</phone>
    <email>brigitte.ranque@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre de Recherches er de Lutte contre la Drépanocytose</name>
      <address>
        <city>Bamako</city>
        <country>Mali</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dapa Diallo, MD</last_name>
      <phone>0022320223898</phone>
      <email>da.diallo@laposte.net</email>
    </contact>
    <investigator>
      <last_name>Dapa Diallo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre National de Transfusion Sanguine</name>
      <address>
        <city>Dakar</city>
        <country>Senegal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saliou Diop, MD</last_name>
      <phone>(221) 33 869 86 60</phone>
      <email>saliou.diop@ucad.edu.sn</email>
    </contact>
    <investigator>
      <last_name>Saliou Diop, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mali</country>
    <country>Senegal</country>
  </location_countries>
  <reference>
    <citation>Ranque B, Menet A, Diop IB, Thiam MM, Diallo D, Diop S, Diagne I, Sanogo I, Kingue S, Chelo D, Wamba G, Diarra M, Anzouan JB, N'Guetta R, Diakite CO, Traore Y, Legueun G, Deme-Ly I, Belinga S, Boidy K, Kamara I, Tharaux PL, Jouven X. Early renal damage in patients with sickle cell disease in sub-Saharan Africa: a multinational, prospective, cross-sectional study. Lancet Haematol. 2014 Nov;1(2):e64-73. doi: 10.1016/S2352-3026(14)00007-6. Epub 2014 Oct 28.</citation>
    <PMID>27030156</PMID>
  </reference>
  <reference>
    <citation>Ranque B, Menet A, Boutouyrie P, Diop IB, Kingue S, Diarra M, N'Guetta R, Diallo D, Diop S, Diagne I, Sanogo I, Tolo A, Chelo D, Wamba G, Gonzalez JP, Abough'elie C, Diakite CO, Traore Y, Legueun G, Deme-Ly I, Faye BF, Seck M, Kouakou B, Kamara I, Le Jeune S, Jouven X. Arterial Stiffness Impairment in Sickle Cell Disease Associated With Chronic Vascular Complications: The Multinational African CADRE Study. Circulation. 2016 Sep 27;134(13):923-33. doi: 10.1161/CIRCULATIONAHA.115.021015. Epub 2016 Aug 31.</citation>
    <PMID>27582423</PMID>
  </reference>
  <reference>
    <citation>Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev. 2007 Jan;21(1):37-47. Epub 2006 Nov 7. Review.</citation>
    <PMID>17084951</PMID>
  </reference>
  <reference>
    <citation>Hebbel RP. Reconstructing sickle cell disease: a data-based analysis of the &quot;hyperhemolysis paradigm&quot; for pulmonary hypertension from the perspective of evidence-based medicine. Am J Hematol. 2011 Feb;86(2):123-54. doi: 10.1002/ajh.21952. Review.</citation>
    <PMID>21264896</PMID>
  </reference>
  <reference>
    <citation>Tharaux PL. Endothelin in renal injury due to sickle cell disease. Contrib Nephrol. 2011;172:185-99. doi: 10.1159/000328699. Epub 2011 Aug 30. Review.</citation>
    <PMID>21893999</PMID>
  </reference>
  <reference>
    <citation>Connes P, Lamarre Y, Hardy-Dessources MD, Lemonne N, Waltz X, Mougenel D, Mukisi-Mukaza M, Lalanne-Mistrih ML, Tarer V, Tressières B, Etienne-Julan M, Romana M. Decreased hematocrit-to-viscosity ratio and increased lactate dehydrogenase level in patients with sickle cell anemia and recurrent leg ulcers. PLoS One. 2013 Nov 4;8(11):e79680. doi: 10.1371/journal.pone.0079680. eCollection 2013.</citation>
    <PMID>24223994</PMID>
  </reference>
  <reference>
    <citation>Bunn HF, Nathan DG, Dover GJ, Hebbel RP, Platt OS, Rosse WF, Ware RE. Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood. 2010 Aug 5;116(5):687-92. doi: 10.1182/blood-2010-02-268193. Epub 2010 Apr 15. Review.</citation>
    <PMID>20395414</PMID>
  </reference>
  <reference>
    <citation>Kato GJ, McGowan V, Machado RF, Little JA, Taylor J 6th, Morris CR, Nichols JS, Wang X, Poljakovic M, Morris SM Jr, Gladwin MT. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood. 2006 Mar 15;107(6):2279-85. Epub 2005 Nov 15.</citation>
    <PMID>16291595</PMID>
  </reference>
  <reference>
    <citation>Kato GJ, Hebbel RP, Steinberg MH, Gladwin MT. Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions. Am J Hematol. 2009 Sep;84(9):618-25. doi: 10.1002/ajh.21475.</citation>
    <PMID>19610078</PMID>
  </reference>
  <reference>
    <citation>Nouraie M, Lee JS, Zhang Y, Kanias T, Zhao X, Xiong Z, Oriss TB, Zeng Q, Kato GJ, Gibbs JS, Hildesheim ME, Sachdev V, Barst RJ, Machado RF, Hassell KL, Little JA, Schraufnagel DE, Krishnamurti L, Novelli E, Girgis RE, Morris CR, Rosenzweig EB, Badesch DB, Lanzkron S, Castro OL, Goldsmith JC, Gordeuk VR, Gladwin MT; Walk-PHASST Investigators and Patients. The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. Haematologica. 2013 Mar;98(3):464-72. doi: 10.3324/haematol.2012.068965. Epub 2012 Sep 14.</citation>
    <PMID>22983573</PMID>
  </reference>
  <reference>
    <citation>Aessopos A, Farmakis D, Tsironi M, Diamanti-Kandarakis E, Matzourani M, Fragodimiri C, Hatziliami A, Karagiorga M. Endothelial function and arterial stiffness in sickle-thalassemia patients. Atherosclerosis. 2007 Apr;191(2):427-32. Epub 2006 May 18.</citation>
    <PMID>16712855</PMID>
  </reference>
  <reference>
    <citation>Tharaux PL, Girot R, Kanfer A, Dussaule JC, Gaitz JP, Tribout L, Baudot N, Vayssairat M. Cutaneous microvascular blood flow and reactivity in patients with homozygous sickle cell anaemia. Eur J Haematol. 2002 Jun;68(6):327-31.</citation>
    <PMID>12225389</PMID>
  </reference>
  <reference>
    <citation>van Beers EJ, Schaap MC, Berckmans RJ, Nieuwland R, Sturk A, van Doormaal FF, Meijers JC, Biemond BJ; CURAMA study group. Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. Haematologica. 2009 Nov;94(11):1513-9. doi: 10.3324/haematol.2009.008938. Epub 2009 Oct 8.</citation>
    <PMID>19815831</PMID>
  </reference>
  <reference>
    <citation>Donadee C, Raat NJ, Kanias T, Tejero J, Lee JS, Kelley EE, Zhao X, Liu C, Reynolds H, Azarov I, Frizzell S, Meyer EM, Donnenberg AD, Qu L, Triulzi D, Kim-Shapiro DB, Gladwin MT. Nitric oxide scavenging by red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell storage lesion. Circulation. 2011 Jul 26;124(4):465-76. doi: 10.1161/CIRCULATIONAHA.110.008698. Epub 2011 Jul 11.</citation>
    <PMID>21747051</PMID>
  </reference>
  <reference>
    <citation>Nebor D, Bowers A, Connes P, Hardy-Dessources MD, Knight-Madden J, Cumming V, Reid M, Romana M. Plasma concentration of platelet-derived microparticles is related to painful vaso-occlusive phenotype severity in sickle cell anemia. PLoS One. 2014 Jan 24;9(1):e87243. doi: 10.1371/journal.pone.0087243. eCollection 2014.</citation>
    <PMID>24475257</PMID>
  </reference>
  <reference>
    <citation>Camus SM, Gausserès B, Bonnin P, Loufrani L, Grimaud L, Charue D, De Moraes JA, Renard JM, Tedgui A, Boulanger CM, Tharaux PL, Blanc-Brude OP. Erythrocyte microparticles can induce kidney vaso-occlusions in a murine model of sickle cell disease. Blood. 2012 Dec 13;120(25):5050-8. doi: 10.1182/blood-2012-02-413138. Epub 2012 Sep 13.</citation>
    <PMID>22976952</PMID>
  </reference>
  <reference>
    <citation>Reiter CD, Wang X, Tanus-Santos JE, Hogg N, Cannon RO 3rd, Schechter AN, Gladwin MT. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med. 2002 Dec;8(12):1383-9. Epub 2002 Nov 11.</citation>
    <PMID>12426562</PMID>
  </reference>
  <reference>
    <citation>Turhan A, Weiss LA, Mohandas N, Coller BS, Frenette PS. Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3047-51.</citation>
    <PMID>11880644</PMID>
  </reference>
  <reference>
    <citation>Chaar V, Picot J, Renaud O, Bartolucci P, Nzouakou R, Bachir D, Galactéros F, Colin Y, Le Van Kim C, El Nemer W. Aggregation of mononuclear and red blood cells through an {alpha}4{beta}1-Lu/basal cell adhesion molecule interaction in sickle cell disease. Haematologica. 2010 Nov;95(11):1841-8. doi: 10.3324/haematol.2010.026294. Epub 2010 Jun 18.</citation>
    <PMID>20562314</PMID>
  </reference>
  <reference>
    <citation>El Nemer W, Wautier MP, Rahuel C, Gane P, Hermand P, Galactéros F, Wautier JL, Cartron JP, Colin Y, Le Van Kim C. Endothelial Lu/BCAM glycoproteins are novel ligands for red blood cell alpha4beta1 integrin: role in adhesion of sickle red blood cells to endothelial cells. Blood. 2007 Apr 15;109(8):3544-51. Epub 2006 Dec 7.</citation>
    <PMID>17158232</PMID>
  </reference>
  <reference>
    <citation>Chen G, Zhang D, Fuchs TA, Manwani D, Wagner DD, Frenette PS. Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease. Blood. 2014 Jun 12;123(24):3818-27. doi: 10.1182/blood-2013-10-529982. Epub 2014 Mar 11.</citation>
    <PMID>24620350</PMID>
  </reference>
  <reference>
    <citation>Tournamille C, Colin Y, Cartron JP, Le Van Kim C. Disruption of a GATA motif in the Duffy gene promoter abolishes erythroid gene expression in Duffy-negative individuals. Nat Genet. 1995 Jun;10(2):224-8.</citation>
    <PMID>7663520</PMID>
  </reference>
  <reference>
    <citation>Connes P, Lamarre Y, Waltz X, Ballas SK, Lemonne N, Etienne-Julan M, Hue O, Hardy-Dessources MD, Romana M. Haemolysis and abnormal haemorheology in sickle cell anaemia. Br J Haematol. 2014 May;165(4):564-72. doi: 10.1111/bjh.12786. Epub 2014 Feb 24.</citation>
    <PMID>24611951</PMID>
  </reference>
  <reference>
    <citation>Bollée G, Flamant M, Schordan S, Fligny C, Rumpel E, Milon M, Schordan E, Sabaa N, Vandermeersch S, Galaup A, Rodenas A, Casal I, Sunnarborg SW, Salant DJ, Kopp JB, Threadgill DW, Quaggin SE, Dussaule JC, Germain S, Mesnard L, Endlich K, Boucheix C, Belenfant X, Callard P, Endlich N, Tharaux PL. Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritis. Nat Med. 2011 Sep 25;17(10):1242-50. doi: 10.1038/nm.2491. Erratum in: Nat Med. 2011 Oct;17(10):2 p following 1250. Nat Med. 2011 Nov;17(11):1521.</citation>
    <PMID>21946538</PMID>
  </reference>
  <reference>
    <citation>Sabaa N, de Franceschi L, Bonnin P, Castier Y, Malpeli G, Debbabi H, Galaup A, Maier-Redelsperger M, Vandermeersch S, Scarpa A, Janin A, Levy B, Girot R, Beuzard Y, Leboeuf C, Henri A, Germain S, Dussaule JC, Tharaux PL. Endothelin receptor antagonism prevents hypoxia-induced mortality and morbidity in a mouse model of sickle-cell disease. J Clin Invest. 2008 May;118(5):1924-33. doi: 10.1172/JCI33308.</citation>
    <PMID>18382768</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2017</study_first_submitted>
  <study_first_submitted_qc>November 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2017</study_first_posted>
  <last_update_submitted>November 22, 2017</last_update_submitted>
  <last_update_submitted_qc>November 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sickle cell disease</keyword>
  <keyword>anemia</keyword>
  <keyword>Africa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

